Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects

Table 2 Summary of studies correlating the Oxford classification for immunoglobulin a nephropathy with clinical outcomes

Study	Patients (n)	End point	Univariate analysis	Multivariate analysis
Coppo et al[19]	206 A, 59 C	Rate of eGFR decline	M, E, S T	M, E, S, T
Herzenberg et al[20]	143 A, 44 C	Rate of eGFR decline	Not done	E, S, T
Katafuchi et al[21]	702 A, C	ESRD	Not done	S, T
Zeng et al[22]	1026 A	Rate of eGFR decline	M, S, T	M, T
Shi et al[23]	410 A	ESRD	M, S, T	S, T
Edström Halling et al[24]	99 C	GFR reduction > 50%, ESRD	M, E, T	E
Shima et al[25]	161 C	eGFR < 60% mL/min per 1.73m2	M, T	M, T
Coppo et al[26]	973 A, 174 C	Rate of eGFR decline	M, E, S, T	S, T
Alamartine et al[27]	183 A	Doubling of SCr or ESRD	E, S, T	None
El Karoui et al[28]	128 A	Rate of eGFR decline	Not done	T
Lee et al[29]	69 A	GFR reduction > 50%, ESRD	E, T	E
Kang et al[30]	197 A	GFR reduction > 50%, ESRD	T	T
Le et al[31]	218 C	eGFR reduction > 50%, ESRD	T, S	T

A: Adults; C: Children; eGFR: Estimated glomerular filtration rate; E: Endothelial hypercellularity; ESRD: End-stage renal disease; GFR: Glomerular filtration rate; M: Mesangial hypercellularity; S: Segmental sclerosis; Scr: Serum creatinine; T: Tubular atrophy/interstitial fibrosis.